Dual versus single antiplatelet therapy in patients with nonminor ischemic stroke: a meta-analysis

Abstract

Background Patients with ischemic stroke present a higher risk of stroke recurrence, neurological deterioration, and death. The benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) among patients with minor ischemic stroke is well established; however, robust evidence is lacking for those with nonminor stroke.

Objective To describe the benefits and risks of DAPT versus SAPT in patients with nonminor ischemic stroke.

Methods We searched the PubMed, Embase, and Cochrane Library databases for articles published from inception to April 2024. Data were collected from randomized clinical trials and observational studies comparing DAPT to SAPT following nonminor ischemic stroke, defined by a score ≥ 4 on the National Institutes of Health Stroke Scale (NIHSS).

Results In total, 6 studies were included, comprising 12,480 patients. The NIHSS score at baseline from the selected studies ranged from 4 to 15. There was no significant difference between DAPT and SAPT for recurrent stroke (risk ratio [RR] = 0.91; 95% confidence interval [95%CI] = 0.82–1.01; p = 0.09; I² = 0%), ischemic stroke (RR = 0.89; 95%CI = 0.80–1.00; p = 0.05; I² = 0%) or hemorrhagic stroke (RR = 1.23; 95%CI = 0.41-3.99; p = 0.66; I² = 27%). Major bleeding was not significantly increased in the DAPT group compared with the SAPT group (RR = 0.87; 95%CI = 0.29–2.66; p = 0.81; I² = 44%). The overall analysis did not show a significant difference in all-cause mortality (RR = 0.72; 95%CI = 0.50–1.02; p = 0.07; I² = 0%).

Conclusion There was no difference between DAPT and SAPT regarding recurrent stroke, ischemic stroke, hemorrhagic stroke, major bleeding, or overall mortality.

Keywords

Ischemic Stroke - Dual Anti-platelet Therapy - Clopidogrel - Ticagrelor - Aspirin

Authors' Contributions

IM: idea for the article and conception and design, literature search, data acquisition, writing – original draft, writing – review and editing, and figures; GM: conception and design, data analysis, writing – review and editing, and figures; ML: literature search, data analysis, and writing – original draft; GAM: data acquisition, data analysis, writing – original draft, writing – review and editing, and figures; ACP: design, and critical revision of the work; and JPMT: design, writing – review and editing, and critical revision of the work. All authors read and approved the final manuscript.

Editor-in-Chief: Ayrton Roberto Massaro.

Associate Editor: Octavio Marques Pontes Neto.

Publikationsverlauf

Eingereicht: 03. Juli 2024

Angenommen: 29. September 2024

Artikel online veröffentlicht:
24. Februar 2025

• References

• 1 Skajaa N, Adelborg K, Horváth-Puhó E. et al. Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark: A Nationwide Registry Study. Neurology 2022; 98 (04) e329-e342
• 2 Coutts SB, Hill MD, Campos CR. et al; VISION study group. Recurrent events in transient ischemic attack and minor stroke: what events are happening and to which patients?. Stroke 2008; 39 (09) 2461-2466
• 3 Siegler JE, Martin-Schild S. Early Neurological Deterioration (END) after stroke: the END depends on the definition. Int J Stroke 2011; 6 (03) 211-212
• 4 Schmidt M, Jacobsen JB, Johnsen SP, Bøtker HE, Sørensen HT. Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity. Neurology 2014; 82 (04) 340-350
• 5 Dawson J, Merwick Á, Webb A, Dennis M, Ferrari J, Fonseca AC. European Stroke Organisation. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J 2021; 6 (02) CLXXXVII-CXCI
• 6 Powers WJ, Rabinstein AA, Ackerson T. et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019; 50 (12) e344-e418
• 7 Li M, Yang Q, Shi J, Zhang X, Lin H, Ge F. Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. BMC Neurol 2023; 23 (01) 303
• 8 Wang Y, Liu M, Pu C. 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. Int J Stroke 2017; 12 (03) 302-320
• 9 Lun R, Dhaliwal S, Zitikyte G, Roy DC, Hutton B, Dowlatshahi D. Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. JAMA Neurol 2022; 79 (02) 141-148
• 10 Wang Y, Pan Y, Li H. et al; THALES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA Neurol 2021; 78 (09) 1091-1098
• 11 Chen H-S, Cui Y, Wang X-H. et al; ATAMIS investigators. Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial. JAMA Neurol 2024; 81 (05) 450-460
• 12 Marinheiro G, Araújo B, Monteiro GA. et al. Ticagrelor versus clopidogrel in dual antiplatelet therapy after minor stroke or transient ischemic attack: an updated network meta-analysis. J Neurol 2024; 271 (06) 3030-3038
• 13 Sterne JA, Hernán MA, Reeves BC. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919
• 14 Sterne JAC, Savović J, Page MJ. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898
• 15 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
• 16 Higgins J, Thomas J, Chandler J. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). 2023 www.training.cochrane.org/handbook (accessed 21 April 2024)
• 17 Wang L, Zhou Q, Gu H. et al. Treatment Strategies and Prognosis for Moderate Stroke Patients in China. Cerebrovasc Dis 2024; 53 (05) 547-555
• 18 Khazaal O, Rothstein A, Husain MR. et al. Dual-Antiplatelet Therapy May Not Be Associated With an Increased Risk of In-hospital Bleeding in Patients With Moderate or Severe Ischemic Stroke. Front Neurol 2021; 12: 728111
• 19 Kim J-T, Park M-S, Choi K-H. et al. Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study. Stroke 2019; 50 (11) 3147-3155
• 20 Downey J, Blackwell S, Germain K, Pinner NA, Starr JA. Dual Antiplatelet Therapy After an Acute Nonminor Stroke. J Pharm Technol 2023; 39 (02) 51-54
• 21 Xiong Y, Gu H, Zhao X-Q. et al. Clinical Characteristics and In-Hospital Outcomes of Varying Definitions of Minor Stroke: From a Large-Scale Nation-Wide Longitudinal Registry. Stroke 2021; 52 (04) 1253-1258
• 22 Wang Y, Wang Y, Zhao X. et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369 (01) 11-19
• 23 Johnston SC, Easton JD, Farrant M. et al; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018; 379 (03) 215-225
• 24 Johnston SC, Amarenco P, Denison H. et al; THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med 2020; 383 (03) 207-217
• 25 Gao Y, Chen W, Pan Y. et al; INSPIRES Investigators. Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke. N Engl J Med 2023; 389 (26) 2413-2424
• 26 Fischer U, Baumgartner A, Arnold M. et al. What is a minor stroke?. Stroke 2010; 41 (04) 661-666
• 27 Venketasubramanian N. Ischemic Stroke: New Insights from Risk Factors, Mechanisms and Outcomes. J Cardiovasc Dev Dis 2023; 10 (12) 472
• 28 Tsai C-F, Anderson N, Thomas B, Sudlow CL. Risk factors for ischemic stroke and its subtypes in Chinese vs. Caucasians: Systematic review and meta-analysis. Int J Stroke 2015; 10 (04) 485-493
• 29 Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103 (06) 1128-1135
• 30 Bhatia K, Ladd LM, Carr KH. et al. Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. Curr Neurol Neurosci Rep 2023; 23 (05) 235-262
• 31 van Kranendonk KR, Treurniet KM, Boers AMM. et al; MR CLEAN investigators. Hemorrhagic transformation is associated with poor functional outcome in patients with acute ischemic stroke due to a large vessel occlusion. J Neurointerv Surg 2019; 11 (05) 464-468
• 32 Krishnan R, Mays W, Elijovich L. Complications of Mechanical Thrombectomy in Acute Ischemic Stroke. Neurology 2021; 97 (20, Suppl 2) S115-S125
• 33 Zhang J, Yang Y, Sun H, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2014; 2 (08) 81-81
• 34 Aslanyan S, Weir CJ, Johnston SC, Lees KR. GAIN International Steering Committee and Investigators. Poststroke neurological improvement within 7 days is associated with subsequent deterioration. Stroke 2004; 35 (09) 2165-2170
• 35 Park J-H, Ovbiagele B. Relationship of functional disability after a recent stroke with recurrent stroke risk. Eur J Neurol 2016; 23 (02) 361-367
• 36 Ganesh A, Luengo-Fernandez R, Wharton RM, Rothwell PM. Oxford Vascular Study. Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke. Neurology 2018; 91 (21) e1951-e1960